| ITC recommendations for transporter kinetic parameter estimation and translational modeling of transport‐mediated PK and DDIs in humans MJ Zamek‐Gliszczynski, CA Lee, A Poirier, J Bentz, X Chu, H Ellens, ... Clinical Pharmacology & Therapeutics 94 (1), 64-79, 2013 | 218 | 2013 |
| Transporters in drug development: 2018 ITC recommendations for transporters of emerging clinical importance MJ Zamek‐Gliszczynski, ME Taub, PP Chothe, X Chu, KM Giacomini, ... Clinical Pharmacology & Therapeutics 104 (5), 890-899, 2018 | 214 | 2018 |
| Variability in P-glycoprotein inhibitory potency (IC50) using various in vitro experimental systems: implications for universal digoxin drug-drug interaction risk assessment … J Bentz, MP O’Connor, D Bednarczyk, JA Coleman, C Lee, J Palm, ... Drug metabolism and disposition 41 (7), 1347-1366, 2013 | 169 | 2013 |
| Breast cancer resistance protein (ABCG2) in clinical pharmacokinetics and drug interactions: practical recommendations for clinical victim and perpetrator drug-drug interaction … CA Lee, MA O’Connor, TK Ritchie, A Galetin, JA Cook, ... Drug metabolism and disposition 43 (4), 490-509, 2015 | 146 | 2015 |
| Functional assessment of multiple P-glycoprotein (P-gp) probe substrates: influence of cell line and modulator concentration on P-gp activity ME Taub, L Podila, D Ely, I Almeida Drug Metabolism and Disposition 33 (11), 1679-1687, 2005 | 146 | 2005 |
| Optimized conditions for MDCK permeability and turbidimetric solubility studies using compounds representative of BCS classes I–IV ME Taub, L Kristensen, S Frokjaer European journal of pharmaceutical sciences 15 (4), 331-340, 2002 | 97 | 2002 |
| Dipeptide model prodrugs for the intestinal oligopeptide transporter. Affinity for and transport via hPepT1 in the human intestinal Caco-2 cell line CU Nielsen, R Andersen, B Brodin, S Frokjaer, ME Taub, B Steffansen Journal of Controlled Release 76 (1-2), 129-138, 2001 | 89 | 2001 |
| Brefeldin A enhances receptor-mediated transcytosis of transferrin in filter-grown Madin-Darby canine kidney cells. J Wan, ME Taub, D Shah, WC Shen Journal of Biological Chemistry 267 (19), 13446-13450, 1992 | 84 | 1992 |
| Digoxin is not a substrate for organic anion-transporting polypeptide transporters OATP1A2, OATP1B1, OATP1B3, and OATP2B1 but is a substrate for a sodium-dependent transporter … ME Taub, K Mease, RS Sane, CA Watson, L Chen, H Ellens, B Hirakawa, ... Drug metabolism and disposition 39 (11), 2093-2102, 2011 | 80 | 2011 |
| The use of transporter probe drug cocktails for the assessment of transporter-based drug–drug interactions in a clinical setting—proposal of a four component transporter cocktail T Ebner, N Ishiguro, ME Taub Journal of pharmaceutical sciences 104 (9), 3220-3228, 2015 | 73 | 2015 |
| Differential selectivity of efflux transporter inhibitors in Caco-2 and MDCK–MDR1 monolayers: A strategy to assess the interaction of a new chemical entity with P-gp, BCRP, and … K Mease, R Sane, L Podila, ME Taub Journal of pharmaceutical sciences 101 (5), 1888-1897, 2012 | 70 | 2012 |
| Bridging in vitro and in vivo metabolism and transport of faldaprevir in human using a novel cocultured human hepatocyte system, HepatoPac D Ramsden, DJ Tweedie, TS Chan, ME Taub, Y Li Drug metabolism and Disposition 42 (3), 394-406, 2014 | 68 | 2014 |
| Pharmacokinetic evaluation of a drug transporter cocktail consisting of digoxin, furosemide, metformin, and rosuvastatin P Stopfer, T Giessmann, K Hohl, A Sharma, N Ishiguro, ME Taub, ... Clinical Pharmacology & Therapeutics 100 (3), 259-267, 2016 | 64 | 2016 |
| Enzymatic barriers to peptide and protein drug delivery VHL Lee, RD Traver, ME Taub Peptide and protein drug delivery 1, 303-358, 1991 | 45 | 1991 |
| Application of receiver operating characteristic analysis to refine the prediction of potential digoxin drug interactions H Ellens, S Deng, JA Coleman, J Bentz, ME Taub, I Ragueneau-Majlessi, ... Drug Metabolism and Disposition 41 (7), 1367-1374, 2013 | 44 | 2013 |
| Sex-, species-, and tissue-specific metabolism of empagliflozin in male mouse kidney forms an unstable hemiacetal metabolite (M466/2) that degrades to 4-hydroxycrotonaldehyde … ME Taub, E Ludwig-Schwellinger, N Ishiguro, W Kishimoto, H Yu, ... Chemical Research in Toxicology 28 (1), 103-115, 2015 | 42 | 2015 |
| Mechanisms underlying benign and reversible unconjugated hyperbilirubinemia observed with faldaprevir administration in hepatitis C virus patients RS Sane, GG Steinmann, Q Huang, Y Li, L Podila, K Mease, S Olson, ... Journal of Pharmacology and Experimental Therapeutics 351 (2), 403-412, 2014 | 40 | 2014 |
| Optimization of a drug transporter probe cocktail: potential screening tool for transporter‐mediated drug–drug interactions P Stopfer, T Giessmann, K Hohl, S Hutzel, S Schmidt, D Gansser, ... British journal of clinical pharmacology 84 (9), 1941-1949, 2018 | 39 | 2018 |
| Stability, metabolism and transport of d-Asp (OBzl)–Ala—a model prodrug with affinity for the oligopeptide transporter B Steffansen, EI Lepist, ME Taub, BD Larsen, S Frokjaer, H Lennernäs European journal of pharmaceutical sciences 8 (1), 67-73, 1999 | 39 | 1999 |
| Validation of a drug transporter probe cocktail using the prototypical inhibitors rifampin, probenecid, verapamil, and cimetidine ST Wiebe, T Giessmann, K Hohl, S Schmidt-Gerets, E Hauel, ... Clinical Pharmacokinetics 59, 1627-1639, 2020 | 37 | 2020 |
Naoki Ishiguro Nagoya University在 med.nagoya-u.ac.jp 的电子邮件经过验证
